CD164 Antibody (502021) [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # FAB5790Z
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG3 Clone # 502021
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
NS0 mouse myeloma cell line transfected with human CD14
Asp24-Leu197
Accession # Q04900
Asp24-Leu197
Accession # Q04900
Specificity
Detects human CD164 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse CD164 is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG3
Applications for CD164 Antibody (502021) [DyLight 755]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD164
Alternate Names
CD164, MGC-24, MUC-24
Gene Symbol
CD164
Additional CD164 Products
Product Documents for CD164 Antibody (502021) [DyLight 755]
Product Specific Notices for CD164 Antibody (502021) [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...